Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Managing antiphospholipid syndrome in pregnancy

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparison of disseminated intravascular coagulation in trauma with coagulopathy of trauma/acute coagulopathy of trauma-shock

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Adriano Alatri
  • Anna-Elina Armstrong
  • Andreas Greinacher
  • Andreas Koster
  • Sibylle A Kozek-Langenecker
  • Marcus D Lancé
  • Andreas Link
  • Jørn D Nielsen
  • Per M Sandset
  • Alexander J Spanjersberg
  • Michael Spannagl
Vis graf over relationer
Argatroban has been introduced as an alternative parenteral anticoagulant for HIT-patients in several European countries in 2005. In 2009 a panel of experts discussed their clinical experience with argatroban balancing risks and benefits of argatroban treatment in managing the highly procoagulant status of HIT-patients. This article summarizes the main conclusions of this round table discussion. An ongoing issue is the appropriate dosing of argatroban in special patient groups. Therefore, dosing recommendations for different HIT-patient groups (ICU patients; non-ICU patients, paediatric patients, and for patients undergoing renal replacement therapies) are summarized in this consensus statement. Because of the strong correlation between argatroban dosing requirements and scores used to characterize the severity of illness (APACHE; SAPS, SOFA) suitable dosing nomograms are given. This consensus statement contributes to clinically relevant information on the appropriate use and monitoring of argatroban based on the current literature, and provides additional information from clinical experience. As the two other approved drugs for HIT, danaparoid and lepirudin are either currently not available due to manufacturing problems (danaparoid) or will be withdrawn from the market in 2012 (lepirudin), this report should guide physicians who have limited experience with argatroban how to use this drug safely in patients with HIT.
OriginalsprogEngelsk
TidsskriftThrombosis Research
Vol/bind129
Udgave nummer4
Sider (fra-til)426-33
Antal sider8
ISSN0049-3848
DOI
StatusUdgivet - 2012

ID: 36764745